Methotrexate‐associated alterations of the folate and methyl‐transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity

@article{Vezmar2009MethotrexateassociatedAO,
  title={Methotrexate‐associated alterations of the folate and methyl‐transfer pathway in the CSF of ALL patients with and without symptoms of neurotoxicity},
  author={S. Vezmar and P. Sch{\"u}sseler and A. Becker and U. Bode and U. Jaehde},
  journal={Pediatric Blood & Cancer},
  year={2009},
  volume={52}
}
  • S. Vezmar, P. Schüsseler, +2 authors U. Jaehde
  • Published 2009
  • Medicine
  • Pediatric Blood & Cancer
  • Severe neurotoxicity has been observed after systemic high‐dose and intrathecal methotrexate (MTX) treatment. The role of biochemical MTX‐induced alterations of the folate and methyl‐transfer pathway in the development of neurotoxic symptoms is not yet fully elucidated. 
    50 Citations
    New mechanisms for an old drug; DHFR- and non-DHFR-mediated effects of methotrexate in cancer cells.
    • 37
    • PDF
    Acute leukoencephalopathy due to pyrimethamine. An insight into methotrexate neurotoxicity?
    • 3

    References

    SHOWING 1-10 OF 48 REFERENCES
    Evidence for CSF accumulation of 5-methyltetrahydrofolate during repeated courses of methotrexate plus folinic acid rescue.
    • 19
    Demyelination and single-carbon transfer pathway metabolites during the treatment of acute lymphoblastic leukemia: CSF studies.
    • 62
    Biochemical and Clinical Aspects of Methotrexate Neurotoxicity
    • 198
    Rescue from high-dose methotrexate with 5-methyltetrahydrofolate.
    • 10
    Evidence for hypomethylation in two children with acute lymphoblastic leukemia and leukoencephalopathy
    • 48
    • Highly Influential
    Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer.
    • 171
    Demyelination and decreased S‐adenosylmethionine in 5.10‐methylenetetrahydrofolate reductase deficiency
    • 120
    High dose systemic methotrexate-associated acute neurologic dysfunction.
    • 59